Aspartes Pharmaceuticals

Aspartes is a pre-clinical stage biotechnology company focused on developing innovative therapies that target the metabolic dependencies of cancer cells. The company's core technology centers on inhibiting the aspartate transporter SLC1A3, also known as EAAT1, which is upregulated in several aggressive solid tumors to support rapid proliferation. By blocking the uptake of exogenous aspartate, Aspartes' small molecule candidates aim to disrupt nucleotide synthesis and redox balance within the tumor microenvironment. This approach provides a targeted strategy to treat cancers that have become reliant on specific nutrient pathways for survival. Founded on research from the University of Pennsylvania, the company is advancing its lead programs through early-stage development to address high unmet needs in oncology.